Clinical Perspectives


Chimeric Antigen Receptor Therapy (CAR T) Trial Coming Soon for Relapsed Epithelial Ovarian Cancer

January 10, 2022

CYTALUXX Ovarian Cancer Cells

CAR T therapy is an immunological treatment that uses the body’s own immune system to destroy cancerous cells. Normally, a person’s T cells are responsible for detecting noncancerous "intruders," such as viruses and bacteria. However, by genetically modifying these cells to recognize the unique proteins that are present on the surface of cancer cells, it’s possible to program them to destroy cancerous cells while leaving healthy cells alone.

A team of researchers led by Dr. Jose R. Conejo-Garcia, chair of Moffitt’s Immunology Department, has developed a CAR that introduces Follicle Stimulating Hormone (FSH) into T cells. The new genetically modified CAR T cells seek out and destroy cancer cells expressing an FSH receptor protein found on many ovarian cancer cells.

The U.S. Food and Drug Administration (FDA) cleared an investigational new drug application for a CAR T designed to treat women with relapsed epithelial ovarian cancer.  Clinical trials to recruit participants for the study will be rolled out as soon as February 2022. Dr. Robert M. Wenham, chair of Moffitt’s Department of Gynecologic Oncology, will lead the clinical trials.

"Immunotherapy has been a big breakthrough for some cancers. Being able to translate the personalized therapies, like CAR T, for ovarian could help save thousands of patients each year," said Wenham.

Robert M Wenham, MD Chair, Gynecologic Oncology

Conejo-Garcia and his team plan to expand their CAR technology to other solid tumors in the future, including breast, prostate and pancreatic cancers.

Moffitt Cancer Center is a world leader in providing CAR T therapy in blood cancers and the application in solid tumor trials. We are steadfastly committed to developing new and better strategies for the prevention, screening, diagnosis, and treatment of all types of cancer. Along with the many patients who participate, our CAR T clinical trials can potentially benefit countless individuals whose lives will be impacted by ovarian cancer in the future.

If you’d like to refer a patient to Moffitt Cancer Center, complete our online form or contact a physician liaison for assistance. As part of our efforts to shorten referral times as much as possible, online referrals are typically responded to within 24 - 48 hours.